Daratumumab in Combination With ATRA
NCT02751255
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
all-trans retinoic acid (ATRA)
Sponsor
Amsterdam UMC, location VUmc
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]